Janssen Search
Search results
Working with Global Health Authorities
Article Type: Oncology Working with Global Health Authorities: Many Conversations, One Common Goal The ability to get new therapies to patients can be delayed by months or even years if a company is not able to navigate today’s complex regulatory ...
TransCelerate Biopharma
Janssen Participates in TransCelerate Biopharma to Accelerate Development of New Medicines Janssen and nine other leading biopharmaceutical companies formed TransCelerate BioPharma Inc. (TransCelerate), a non-profit organization dedicated to improving the ...
Husseini K. Manji, M.D., FRCPC
HUSSEINI K. MANJI, M.D., FRCPC GLOBAL THERAPEUTIC AREA HEAD NEUROSCIENCE Husseini K. Manji, M.D., FRCPC is Global Therapeutic Head for Neuroscience at Janssen Research & Development, LLC, one of the Johnson & Johnson pharmaceutical companies. He ...
HIV Treatment and Prevention
Innovations in HIV Treatment and Prevention HIV absorption. Janssen is exploring innovative applications of our HIV medicines to improve treatment and prevention outcomes in hard-to-reach areas by finding ways to reduce the frequency of dosing. We’re also ...
Increasing Sustainable Access to Medicines
Increasing Sustainable Access to Medicines Janssen, as part of its commitment to Global Public Health, cultivates and helps implement innovative pricing and results-based financing models that improve access to our medicines for patients in resource ...
Partner with the Janssen Human Microbiome Institute
Article Type: Disease Interception Accelerator Partner with the Janssen Human Microbiome Institute The Janssen Human Microbiome Institute (JHMI), part of Janssen Research & Development, LLC is focused on understanding the unique and crucial role that ...
Neurodegenerative Disorders: Utilizing biomarker sciences to drive disease understanding, patient identification, and accelerated development
Neurodegenerative Disorders: Utilizing biomarker sciences to drive disease understanding, patient identification, and accelerated development We are in the midst of a scientific renaissance in neurodegeneration, driven by growing evidence of overarching ...
Twenty Years of Progress in Search for an HIV Vaccine
Twenty Years of Progress in Search for an HIV Vaccine The world’s inaugural HIV Vaccine Awareness Day (HVAD) was held 20 years ago. HVAD was created in 1998 to commemorate U.S. President Bill Clinton’s declaration that the world needed – and was capable ...
Sanjaya Singh, Ph.D.
SANJAYA SINGH, Ph.D. GLOBAL HEAD JANSSEN BIOTHERAPEUTICS (JBIO) Sanjaya Singh, Ph.D., is the Global Head of Janssen BioTherapeutics, the biotherapeutics engine of Janssen Research & Development. He is responsible for leading an organization of more ...
Disease Prevention & Interception in Healthcare
Disease Prevention, Disease Interception, and Microbiome Research Platforms Focused on Redefining Healthcare Janssen Research & Development's three new research platforms focus on disease prevention, disease interception, and the microbiome – ...